ArticleJournal of contemporary brachytherapy2026
Surface mould brachytherapy in a completely edentulous hard palate carcinoma using an innovative technique: One size does not fit all.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Surface mould brachytherapy (SMB) in edentulous hard palate cancer patients remains a technical challenge due to issues in prosthetic retention and reproducibility. We present a novel technique for SMB in a completely edentulous patient with a second primary squamous cell carcinoma (SCC) of the hard palate, previously treated with external beam radiotherapy. Material and methods: A 73-year-old edentulous male presented with a 1 cm × 1 cm superficial lesion in the hard palate on the right side, staged as cT1N0M0. Given his prior irradiation and surgical ineligibility, high-dose-rate (HDR) SMB was planned. A unique, interlocking maxillo-mandibular acrylic prosthesis with interlocking struts was designed in collaboration with prosthodontics to provide mould stability. Four 6-F nylon catheters were embedded into the maxillary mould, spaced 1 cm apart. Treatment was delivered using an iridium-192 source at 4 Gy per fraction, twice daily (6-hour interval), to a total dose of 52 Gy over 7 days. Results: The patient developed grade 3 acute mucositis two weeks after treatment, but tolerated the therapy well without the need for hospitalization. Mucositis resolved with conservative management. At a 24-month follow-up, the patient remained disease-free, with preserved speech and swallowing functions, excellent mucosal healing, and no late complications or recurrences observed. Conclusions: This case highlights the feasibility and effectiveness of using a customized interlocking acrylic mould for SMB in edentulous patients. The technique ensured reliable prosthetic retention, precise catheter placement, and optimal dose delivery, resulting in favorable oncologic and functional outcomes. Incorporating prosthodontic principles into the workflow of brachytherapy broadens its application for complex head and neck cancer cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.